Author

E. Yilmaz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:clustering· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

A. Cingoz· 1 shared A. Dutta· 1 shared A. H. Habieb· 1 shared A. Kayabolen· 1 shared A. P. Cribbs· 1 shared A. Yildirim· 1 shared B. Isik· 1 shared C. Kuscu· 1 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cingoz

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Reliability metrics of outcome measures during the single and double leg drop jump tests

H. Celik, A. Yildirim, E. Unver, C. Mavili, E. Yilmaz, F. Ozturk, P. Arpinar-Avsar, S. A. Cinemre

This study assesses the reliability of outcome measures in single and double leg drop jump tests for collegiate athletes, finding high reliability for key metrics in both tests.

bioRxiv · Jul 10, 2022 · PreprintPhysiology

HologLev: Hybrid Magnetic Levitation Platform Integrated with Lensless Holographic Microscopy for Density-Based Cell Analysis

K. Delikoyun, S. Yaman, E. Yilmaz, O. Sarigil, M. Anil Inevi, E. Ozcivici, H. C. Tekin

HologLev combines magnetic levitation with lensless holography for automated, low-cost cell density analysis, enabling cell separation and viability testing.

bioRxiv · Dec 10, 2020Bioengineering

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

X. Wei, J. Yang, S. J. Adair, C. Kuscu, K. Y. Lee, W. Kane, P. E. O'Hara, D. Liu, Y. M. Demirlenk, A. H. Habieb, E. Yilmaz, A. Dutta, T. Bauer, M. Adli

The paper identifies PRMT5 as a synthetic lethal target with gemcitabine in pancreatic cancer using CRISPR screening in a PDX model.

bioRxiv · May 25, 2020Cancer Biology